CA 125 kinetics: A cost-effective clinical tool to evaluate clinical trial outcomes in the 1990s

American Journal of Obstetrics and Gynecology

Volumn 174, Issue 4, 1996, Pages 1241-1254

  Buller, R E ^a   Vasilev, S ^a   DiSaia, P J ^a   Fowler Jr , W C ^a   Creasman, W ^a   Herbst, A L ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

CA 125; clinical trials; ovarian cancer

Indexed keywords

CA 125 ANTIGEN; CISPLATIN; CYCLOPHOSPHAMIDE;

ADULT; AGED; CANCER REGRESSION; CANCER SURVIVAL; COMBINATION CHEMOTHERAPY; CONFERENCE PAPER; COST EFFECTIVENESS ANALYSIS; DOSE RESPONSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; OVARY CANCER; PATIENT SELECTION; PRIORITY JOURNAL; PROGNOSIS; STATISTICAL ANALYSIS;

EID: 0029874867     PISSN: 00029378     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9378(96)70667-1     Document Type: Conference Paper

References (26)

1. B Lund M Hansen OP Hansen HH. Hansen High-dose platinum consisting of combined carboplatin and cisplatin in previously untreated ovarian cancer patients with residual disease J Clin Oncol 7 1989 1469 1473
2. IC Henderson DF Hayes R. Gelman Dose-response in the treatment of breast cancer: a critical review J Clin Oncol 6 1988 1501 1515
3. WM. Hryniuk Dose intensity and lymphoma J Clin Oncol 9 1990 200 203
4. L Levin WM. Hryniuk Dose intensity analysis of chemotherapy regimens in ovarian carcinoma J Clin Oncol 5 1987 756 767
5. Y Ben David B Rosen E Franssen T Einarson I. Zseifer Meta-analysis comparing cisplatin total dose intensity and survival in ovarian cancer Gynecol Oncol 59 1995 93 101
6. L Levin R Simon W. Hryniuk Important of multiagent chemotherapy regimens in ovarian carcinoma: dose intensity analysis J Natl Cancer Inst 85 1993 1732 1742
7. D. Fennelly Dose intensity in advanced ovarian cancer: have we answered the question? Clin Cancer Res 1 1995 575 582
8. EC Kohn G Sarosy A Bicher Dose-intense Taxol: high response rate in patients with platinum-resistant recurrent ovarian cancer J Natl Cancer Inst 86 1994 18 24
9. WP McGuire WJ Hoskins MF Brady Assessment of dose-intensive therapy in suboptimally debulked ovarian cancer: a gynecologic oncology group study J Clin Oncol 13 1995 1589 1599
10. ER Broun JL Belinson JS Berek Salvage therapy for recurrent and refractory ovarian cancer with high-dose chemotherapy and autologous bone marrow support: a Gynecologic Oncology Group pilot study Gynecol Oncol 54 1994 357 361
11. RE Buller ML Berman JD Bloss A Manetta PJ. DiSaia CA125 regression: a model for epithelial ovarian cancer response AM J OBSTET GYNECOL 165 1991 360 367
12. RE Buller ML Berman JD Bloss A Manetta PH. DiSaia Serum CA125 regression in epithelial ovarian cancer: correlation with reassessment findings and survival Gynecol Oncol 47 1992 87 92
13. CA Yedema P Kenemans F Voorhorst CA 125 half-life in ovarian cancer: a multivariate survival analysis Br J Cancer 67 1993 1361 1367
14. A Gadducci P Zola F Landoni Serum half-life of CA 125 during early chemotherapy as an independent prognostic variable for patients with advanced epithelial ovarian cancer: results of a multicentric Italian study Gynecol Oncol 58 1995 42 47
15. RC Bast TL Klug E St. John A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer N Engl J Med 309 1983 883 887
16. GA Omura BN Bundy JS Berek S Curry G Delgado R. Mortel Randomized trial of cyclophosphamide plus cisplatin with or without doxorubicin in ovarian carcinoma: a Gynecologic Oncology Group Study J Clin Oncol 7 1989 457 465
17. MEL van der Burg FB Lammes WLJ Van Putten G. Stoter Ovarian cancer: the prognostic value of the serum half life of CA 125 during induction chemotherapy Gynecol Oncol 30 1988 307 312
18. SB Kaye CR Lewis J Paul Randomized study of two doses of cisplatin with cyclophosphamide in epithelial ovarian cancer Lancet 340 1992 329 333
19. AJ. Dembo Time-dose factors in chemotherapy: expanding the concept of dose-intensity J Clin Oncol 5 1987 695 696
20. WM. Hryniuk The calculation of received dose intensity J Clin Oncol 8 1990 1935 1937
21. RE Buller B Kolb J Connor P DiSaia M. Berman Wound healing vs. tumor growth: when should post-operative chemotherapy be initiated? [Abstract] Gynecol Oncol 46 1992 263
22. PA Canney M Moore PM Wilkinson RD. James Ovarian cancer antigen CA 125: a prospective clinical assessment of its role as a tumour marker Br J Cancer 50 1984 765 769
23. J Blessing B. Anderson Analysis of clinical trials in gynecologic cancer timing and interpretation Gynecol Oncol 23 1986 275 283
24. CA Yedema P Kenemans CM Thomas CA 125 serum levels in the early post-operative period do not reflect tumor reduction obtained by cytoreductive surgery Eur J Cancer 29A 1993 966 971
25. BE Buller ML Berman JD Bloss A Manetta PJ. DiSaia CA 125 regression: a model for epithelial ovarian cancer response AM J OBSTET GYNECOL 165 1991 360 367
26. CA Yedema P Kenemans F Voorhorst CA 125 half-life in ovarian cancer: a multivariate survival analysis Br J Cancer 67 1993 1361 1367